.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
QuintilesIMS
Medtronic
Cipla
Dow
Mallinckrodt
McKinsey
Federal Trade Commission
Healthtrust
Express Scripts

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,906,542

« Back to Dashboard

Which drugs does patent 7,906,542 protect, and when does it expire?


Patent 7,906,542 protects XIFAXAN and is included in two NDAs. There has been one Paragraph IV challenge on Xifaxan.

This patent has eighty-one patent family members in thirty-five countries.

Summary for Patent: 7,906,542

Title:Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin
Abstract:Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin .alpha. and rifaximin .beta., and a poorly crystalline form referred to as rifaximin .gamma., useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
Inventor(s): Viscomi; Giuseppe Claudio (Bologna, IT), Campana; Manuela (Bologna, IT), Braga; Dario (Bologna, IT), Confortini; Donatella (Bologna, IT), Cannata; Vincenzo (Bologna, IT), Righi; Paolo (Bologna, IT), Rosini; Goffredo (Bologna, IT)
Assignee: Alfa Wassermann, S.p.A. (Bologna, IT)
Application Number:12/119,622
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Salix Pharms
XIFAXAN
rifaximin
TABLET;ORAL022554-001Mar 24, 2010RXYesYes► Subscribe► SubscribeYY
Salix Pharms
XIFAXAN
rifaximin
TABLET;ORAL021361-001May 25, 2004RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,906,542

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,158,781Polymorphic forms .alpha., .beta. and .gamma. of rifaximin► Subscribe
7,045,620Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations► Subscribe
7,915,275Use of polymorphic forms of rifaximin for medical preparations► Subscribe
8,835,452Polymorphic forms .alpha., .beta. and .gamma. of rifaximin► Subscribe
8,158,644Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin► Subscribe
7,902,206Polymorphic forms .alpha., .beta. and .gamma. of rifaximin► Subscribe
8,173,801Processes for the production of polymorphic forms of rifaximin► Subscribe
7,612,199Polymorphic forms .alpha., .beta., and .gamma. of rifaximin► Subscribe
7,923,553Processes for the production of polymorphic forms of rifaximin► Subscribe
8,853,231Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,906,542

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina043547► Subscribe
Argentina081991► Subscribe
Argentina081992► Subscribe
Austria361927► Subscribe
Austria421965► Subscribe
Austria421966► Subscribe
Australia2004200964► Subscribe
Australia2004287601► Subscribe
BrazilPI0402382► Subscribe
BrazilPI0407149► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Cipla
Deloitte
McKesson
Farmers Insurance
Colorcon
Chubb
Cerilliant
McKinsey
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot